RBC flags AbbVie as defensive AI winner with strong R&D pipeline
RBC flagged AbbVie as a defensive AI winner alongside Eli Lilly, citing its diversified R&D pipeline and resilient cash flow. The firm reiterated support for AbbVie shares, highlighting potential efficiency gains and revenue growth from AI-driven drug discovery initiatives.
1. RBC's Defensive AI Thesis
RBC Research identified large-cap pharmaceutical companies poised to benefit defensively from AI integration, naming AbbVie alongside Eli Lilly. The firm emphasized that these stocks offer downside protection while capturing upside from AI-driven improvements in drug discovery and development efficiency.
2. AbbVie's Strategic Positioning
AbbVie was highlighted for its diversified pipeline spanning immunology, oncology and neuroscience, backed by robust cash flows to fund AI initiatives. RBC noted that AI tools could streamline AbbVie's R&D processes, potentially accelerating clinical trial timelines and boosting long-term revenue growth.